相关实验视频

Updated: Sep 9, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

对白金敏感性复发性卵巢癌的维持疗法

Fumio Asano¹, Mai Momomura¹, Hiromi Shibuya¹

¹Department of Obstetrics and Gynecology, Kyorin University Faculty of Medicine, Tokyo, Japan.

Journal of gynecologic oncology

|August 29, 2025

概括

对于白金敏感的复发性卵巢癌,贝瓦齐祖马布的维持疗法可能优于先前使用过的多基酶抑制剂 (PARPis). 这一发现有助于选择最佳的治疗策略.

科学领域:

妇科瘤学
医学瘤学
药理学

背景情况:

对敏感性复发性卵巢癌 (PSROC) 进行维持治疗至关重要.
聚基酶抑制剂 (PARPis) 和贝瓦奇祖马布是常见的维护选择.
需要澄清这些药物的有效性.

研究的目的:

在PSROC中比较PARPis与贝瓦齐祖马布作为维持疗法的疗效.
调查之前PARPi给药对治疗选择的影响.
为优化卵巢癌患者的维持治疗策略提供见解.

主要方法:

对接受维持治疗 (PARPi或贝瓦西祖马布) 的81名PSROC患者进行了回顾性分析.
主要终点:化疗后无进展生存期 (PFS).
倾向性得分匹配用于控制混因素.

主要成果:

在PARPi和贝瓦西祖马布之间没有显著的PFS差异 (9个月与12个月).
在之前接触过PARPi的患者中,贝瓦齐祖马布的PFS (12个月) 比PARPi重试 (4个月,p=0. 042) 显著好.
在此前接受PARPi治疗的患者中,与贝瓦西祖马布 (20. 0%) 相比,PARPi重复治疗的复发率更高 (58. 8%).

结论:

对于曾使用过PARPi的PSROC患者,维护性治疗可能会提供更好的结果.
在之前接受治疗的患者中,PARPi的再试验显示出更差的PFS和更高的抗药率.
这些发现支持根据先前治疗史进行个性化的维持治疗选择.

关键词:

贝瓦西祖马布尼拉帕里布其他药物卵巢新生体聚甲酶抑制剂

更多相关视频

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...